Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Rapid Establishment of CHO Cell Lines Producing the Anti-Hepatocyte Growth Factor Antibody SFN68

  • Song, Seong-Won (Graduate Program in Biomaterials Science and Engineering, Yonsei University) ;
  • Lee, Song-Jae (Bioresearch Institute, Yooyoung Pharmaceuticals Co. Ltd.) ;
  • Kim, Chang-Young (Bioresearch Institute, Yooyoung Pharmaceuticals Co. Ltd.) ;
  • Han, Byungryeul (iBio Inc, Samsung Cancer Research Building) ;
  • Oh, Jong-Won (Graduate Program in Biomaterials Science and Engineering, Yonsei University)
  • Received : 2013.05.27
  • Accepted : 2013.06.02
  • Published : 2013.08.28
Download PDF
⟨ Previous Next ⟩

Abstract

Anti-hepatocyte growth factor (anti-HGF) monoclonal antibodies (mAbs) are potential therapeutics against various cancers. Screening for high-producer clones is a time-consuming and complex process and is a major hurdle in the development of therapeutic mAbs. Here, we describe an efficient approach that allows the selection of high-producer Chinese hamster ovary (CHO) cell lines producing the novel anti-HGF mAb SFN68, which was generated previously by immunizing HGF bound to its receptor c-Met. We selected an SFN68-producing parental cell line via transfection of the dihydrofolate reductase-deficient CHO cell line DG44, which was preadapted to serum-free suspension culture, with an SFN68-expression vector. Subsequent gene amplification via multiple passages of the parental cell line in a methotrexate-containing medium over 4 weeks, followed by clonal isolation, enabled us to isolate two cell lines, 2F7 and 2H4, with 3-fold higher specific productivity. We also screened 72 different media formulated with diverse feed and basal media to develop a suboptimized medium. In the established suboptimized medium, the highest anti-HGF mAb yields of the 2F7 and 2H4 clones were 842 and 861 mg/l, respectively, which were about 10.5-fold higher than that of the parental cell line in a non-optimized basal medium. The selected CHO cell lines secreting high titers of SFN68 would be useful for the production of sufficient amounts of antibodies for efficacy evaluation in preclinical and early clinical studies.

Keywords

References

  1. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. 2008. Rational vector design and multipathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36: e96. https://doi.org/10.1093/nar/gkn423
  2. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. 1991. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804. https://doi.org/10.1126/science.1846706
  3. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. 2006. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66: 1721-1729. https://doi.org/10.1158/0008-5472.CAN-05-3329
  4. Cacciatore JJ, Chasin LA, Leonard EF. 2010. Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv. 28: 673-681. https://doi.org/10.1016/j.biotechadv.2010.04.003
  5. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, et al. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98: 7443-7448. https://doi.org/10.1073/pnas.131200498
  6. Cherrington JM, Strawn LM, Shawver LK. 2000. New paradigms for the treatment of cancer: the role of antiangiogenesis agents. Adv. Cancer Res. 79: 1-38. https://doi.org/10.1016/S0065-230X(00)79001-4
  7. Comoglio PM, Giordano S, Trusolino L. 2008. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7: 504-516. https://doi.org/10.1038/nrd2530
  8. Gerber MA, Arunakumari A, Huang D, Goldstein J, McNorton S, Drew B, et al. 2008. Integrated strategies for clone and media formulation selection. Bioprocess Int. 6: 58-63.
  9. Huang YM, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. 2010. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog. 26: 1400-1410. https://doi.org/10.1002/btpr.436
  10. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. 2005. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53: 35-69. https://doi.org/10.1016/j.critrevonc.2004.09.004
  11. Kim K, Hur Y, Ryu EK, Rhim JH, Choi CY, Baek CM, et al. 2007. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet. Biochem. Biophys. Res. Commun. 354: 115-121. https://doi.org/10.1016/j.bbrc.2006.12.164
  12. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al. 2006. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12: 1292-1298. https://doi.org/10.1158/1078-0432.CCR-05-1793
  13. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. 2000. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 60: 6737-6743.
  14. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. 2006. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12: 6144-6152. https://doi.org/10.1158/1078-0432.CCR-05-1418
  15. Morrow JK. 2008. Optimizing transient gene expression: applications expected to move beyond discovery and the preclinical to clinical realm. Genet. Eng. Biotechnol. News. 28: 54-59.
  16. Munshi N, Jeay S, L i Y, Chen CR, France DS, Ashwell MA, et al. 2010. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9: 1544-1553. https://doi.org/10.1158/1535-7163.MCT-09-1173
  17. Omasa T. 2002. Gene amplification and its application in cell and tissue engineering. J. Biosci. Bioeng. 94: 600-605. https://doi.org/10.1016/S1389-1723(02)80201-8
  18. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. 2009. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69: 8009-8016. https://doi.org/10.1158/0008-5472.CAN-08-4889
  19. Renard JM, Spagnoli R, Mazier C, Salles MF, Mandine E. 1988. Evidence that monoclonal antibody production kinetics is related to the integral of the viable cells in batch systems. Biotechnol. Lett. 10: 91-96. https://doi.org/10.1007/BF01024632
  20. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. 1992. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. 12: 5152-5158. https://doi.org/10.1128/MCB.12.11.5152
  21. Rubin JS, Bottaro DP, Aaronson SA. 1993. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta. 1155: 357-371.
  22. Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L. 2000. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol. Bioeng. 67: 585-597. https://doi.org/10.1002/(SICI)1097-0290(20000305)67:5<585::AID-BIT9>3.0.CO;2-H
  23. Tian H, Cronstein BN. 2007. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65: 168-173.
  24. Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. 1994. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 263: 98-101. https://doi.org/10.1126/science.7505952

Cited by

  1. Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression vol.9, pp.None, 2013, https://doi.org/10.3389/fonc.2019.00571